Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

National Taiwan University Hospital20 enrolled

Overview

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary and Secondary Pulmonary Hypertension

Interventions

type-5 phosphodiesterase Inhibitor (Sildenafil)DRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria:Patients with primary and secondary pulmonary arterial hypertension \- Exclusion Criteria:Unstable patients or patients with allergy to sildenafil

Locations (1)

Ping-Hung Kuo

Taipei, Taiwan

Outcomes

Primary Outcomes

mean pulmonary artery pressure

6 min walking distance

WHO functional status

PaO2

Secondary Outcomes

cardiac output

VO2max

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.